Skip to content

Intermittent Oro-Esophageal Tube Feeding Using Individually-Customized 3-Dimensional Printing

Intermittent Oro-Esophageal Tube Feeding Using Individually-Customized 3-Dimensional Printing: Prospective, Single Center, Observational Trial of Superiority

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02822456
Enrollment
24
Registered
2016-07-04
Start date
2015-12-31
Completion date
2020-12-31
Last updated
2019-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia

Keywords

dysphagia, intermittent tube, individual 3D printed guiding tube

Brief summary

The aim of this study is to test the clinical effectiveness of IOE tube using individually customized 3-dimentional printed guiding tube as an alternative to Levin tube feeding when unconscious patients have no choice but tube feeding.

Detailed description

According to standard Guideine of videofluoroscopic swallow study(VFSS), Patients referred to dysphagia(swallowing dysfunction)who were required to tube feeding and medically stable of vital sign, and agreed to participate. Participants with swallowing dysfunction who were classified into three groups (nasogastric tube, traditional intermittent (IOE) tube, individual 3D printed guiding tube) according to VFSS. Both traditional IOE tube and individual 3D printed guiding tube groups will receive training about procedure prior to the first feeding. All participants will be evaluated with satisfaction for tube feeding (EORTC QLQ-H&N35) in 3 days from the start day of the tube feeding. On the day of oral feeding, participants will be evaluated with the questionnaires and clinical examination. If the participant is discharged in a state maintain the tube feeding, investigated further length stay at leaving the hospital. On the 1 month, 3 month from tube feeding, the investigators will follow-up and measure the questionnaires and clinical examination.

Interventions

PROCEDUREVFSS

VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube

Sponsors

Ulsan University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Dysphagia patients to check in VFSS (videofluoroscopic swallow study) * Patients participating in the study agreement * Oral feeding is not possible (Need tube feeding)

Exclusion criteria

* Patient to reject the participation * Crico-pharyngeal incoordination * Impaired esophageal peristalsis * Impaired GI tract * Observed esophageal reflux

Design outcomes

Primary

MeasureTime frameDescription
change of EORTC QLQ - H&N35 index1 month after start of tube feedingDetails (inconvenience, discomfort, altered body image, social activities, family life, pain, ease of learning to use) satisfaction evaluation (3, 9, 10)

Secondary

MeasureTime frameDescription
change Mid-arm circumferencebefore VFSS and 1 month and 3 months after start of tube feeding
change of Serum albuminbefore VFSS and 1 month and 3 months after start of tube feeding
complicationsafter 1st session (3days) and after 1 month, and after 3 monthswhether aspiration pneumonia on Chest Radiography or not, Measurement at leave hospital or start oral feeding can be another endpoint
change of success rate (rate of elimination)after 1st session (3days), after 1 month, and after 3 months
change of EORTC QLQ - H&N35 indexafter 1st session (3days) and after 3 monthsMeasurement at leave hospital or start oral feeding can be another endpoint, Details (inconvenience, discomfort, altered body image, social activities, family life, pain, ease of learning to use) satisfaction evaluation (3, 9, 10)
change of MRS indexbefore VFSS and 1 month and 3 months after start of tube feeding

Countries

South Korea

Contacts

Primary ContactChang Ho Hwang
chhwang1220ciba@gmail.com+82-52-250-8898

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026